Sequestration Threatens Life Sciences, Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sequestration Threatens Life Sciences, Drug Development



Barring a last-minute deal by the US Congress to delay or end the threat of sequestration, a total of $85 billion in across-the-board U.S. government spending cuts will be triggered on March 1, threatening to slow scientific research, the development of innovative drugs and medical devices, and the ability of patients to get access to new therapies, reports Burrill & Company in a press statement.

How big an impact sequestration has on the life sciences will depend on whether action is eventually taken that spares the U.S. Food and Drug Administration and the National Institutes of Health from the cuts, and if not, how these agencies take steps to implement the cuts to their individual budgets, the statement reports.

The FDA is expected to lose $318 million in funding and cut hundreds of jobs to adjust to the lower funding level. For the NIH, sequestration would mean the loss of more than $1.6 billion in funding and reduce the number of grants it issues by more than 2,000, Burrill reports.

“While the political parties remain divided over issues of what mix of spending cuts and taxes are needed to address the country’s budget problems, it appears no one wants to take responsibility for unpopular choices and so we end up with an ax, rather than a scalpel,” says G. Steven Burrill, CEO of Burrill & Company. “The unwillingness to make difficult decisions and reach compromise will harm innovation, weaken our economic strength, and delay patients’ access to new medicines.”

The evolving situation in Washington comes against a backdrop of weakened financing activity for the life sciences sector in February, a month in which activity fell dramatically from levels a year ago. Global venture financings for life sciences companies totaled $582 million in February, a 47% decline from the same period a year ago and the lowest monthly activity in two years. On the public financing side, total global financing transactions for life sciences companies in February reached an anemic $865 million, a 78% drop from the $3.9 billion for the same period a year ago.

In addition to the sequestration drama, the threat of a government shut down looms, unless action is taken to address the current spending bill that is set to expire March 27.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here